
Cannabis for Pain Relief: Case Reviewing the Literature - April 10, 2024
This site is for learners who attended the live April 10, 2024, program to claim credit.
Claiming Credit
Thank you for participating in this program. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to complete the evaluation and claim your credit on the following page.
ADA statement: To request reasonable accommodations for a disability please contact [email protected], in writing, at least two weeks prior to the activity.
Target Audience
Primary care physicians, internists, family practice physicians, nurse practitioners, nurses, and physician assistants
Learning Objectives
- Describe the connection between anxiety and chronic pain
- Describe the use of cannabis for anxiety relative to pain
- Describe the medical evidence for prescribing cannabis directions for pain
- Use patient-centered clinical trial (N of 1 cases) to improve pain management
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program meets the criteria of the Massachusetts Board of Registration in Medicine for 1 hour of opioid education.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 MA Opioid Education Statement
- 1.00 Participation